MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(TSV:NTLX)

1.670 -0.630 (-27.39%)
Delayed Quote Updated: 12:41 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NTLX

News headline image
SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing... 
Via TheNewswire.com
News headline image
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq:... 
Via TheNewswire.com
News headline image
Neurothera Labs Inc. Announces Share Consolidation
Toronto, Ontario – August 28, 2026 –– TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC),... 
Via TheNewswire.com
News headline image
NeuroThera Labs Engages Dr. Reuter Investor Relations
Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC),... 
Via TheNewswire.com
News headline image
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.
Toronto, Ontario – June 3, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the “Company” or “NeuroThera”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd.... 
Via TheNewswire.com
Topics Intellectual Property
News headline image
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story